GRAIL (GRAL) Research & Development: $190.2 Mil (TTM As of Mar. 2026)


GRAL GRAIL Inc GRAL
12 GF Score
Price $65.96
! 2 Warning Signs
View Full Analysis

What is GRAIL Research & Development?

GRAIL GRAL -0.92% 12 Research & Development is $190.2 Mil as of Mar. 2026. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GRAIL's Research & Development for the three months ended in Mar. 2026 was $48.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $190.2 Mil.

GRAIL  (NAS:GRAL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GRAIL Research & Development Related Terms

GRAIL Research & Development Historical Data

* Premium members only.

The historical data trend for GRAIL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRAIL Research & Development Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 167.09 329.58 338.75 322.38 195.79

GRAIL Quarterly Data
Dec18 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.63 46.63 48.65 46.90 48.02
GRAL
12GF Score
GRAIL Inc GRAL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GRAIL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $190.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $190.2 Mil mean?
GRAIL (GRAL) has a Research & Development of $190.2 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on GRAIL and its competitors.
Is GRAIL's Research & Development too high?
GRAIL's current Research & Development is $190.2 Mil. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Research & Development compare to VCYT and ADPT?
GRAIL's Research & Development of $190.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GRAIL and its competitors. GRAIL's current Research & Development is $190.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current Research & Development of $190.2 Mil. The current Research & Development is $190.2 Mil. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GRAIL (GRAL), the current Research & Development is $190.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRAIL Business Description

Other Exchanges NL0:Germany
Address 1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score

Get the complete analysis for GRAL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.96
Price